Psssssst! Have you heard about the new way to control pain? You just did.
Introducing OroCAM (meloxicam), the fi rst and only veterinary NSAID with transmucosal oral delivery. Learn more at
OroCAM.com
quick and reliable delivery1, 2
Indication: OroCAM (meloxicam) Transmucosal Oral Spray is indicated for the control of pain and infl ammation associated with osteoarthritis in dogs.
Important OroCAM (meloxicam) Safety Information: WARNING: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer meloxicam transmucosal oral spray to cats. See Contraindications for detailed information. Warnings, Precautions, and Contraindications: For oral use in dogs only. OroCAM should not be used in dogs with known hypersensitivity to meloxicam or other NSAIDs, dogs weighing less than 5.5 pounds (2.5 kg), or dogs younger than six months of age. It has not been evaluated for safety in breeding dogs, lactating dogs, or dogs with bleeding disorders. Adverse Reactions: Common adverse reactions include vomiting, diarrhea, increased liver enzyme values, and loss of appetite. In clinical studies, the clinical signs were generally mild, transient (lasted 1-4 days during the 28-day study period), and resulted in complete recovery. There were no clinical signs related to the increased liver enzymes. Kidney or liver damage has been reported with other NSAIDs. Other Recommendations: All dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration of any NSAID.
See the Package Insert and Client Information Sheet for complete prescribing and other information.
To learn more about OroCAM, contact Abbott Animal Health Customer Service at 888-299-7416. Promist is a trademark of Velcera, Inc. OroCAM is a trademark of Abbott Laboratories. ORO-053 March 2013 © Abbott Laboratories.
Delivered by Technology
1. OroCAM Spray Studies Summary, Abbott Study 11-11-MC-N-DC-MC, 2011. 2. Placebo-Controlled Field Effi cacy Trial of Meloxicam Administered Orally Via Transmucosal Oral Mist (Promist™
Technology), in Client-Owned Dogs with Osteoarthritis, Abbott Study 09-17-MC-D-CT-MP, 2011.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68